Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc develops cancer medicines based on its proprietary ProTide technology, with news centered on the ADR-listed clinical-stage biopharmaceutical company’s oncology pipeline and corporate updates. Recurring releases describe NUC-7738, a novel anti-cancer agent being studied as a monotherapy in advanced solid tumors and with pembrolizumab in melanoma, and NUC-3373, a 5-fluorouracil-derived new chemical entity being studied with pembrolizumab and docetaxel in advanced solid tumors and lung cancer.
Company updates also cover clinical and translational data presentations, patent protection for NUC-7738, quarterly and annual financial results, cash runway commentary, executive and board changes, and Nasdaq continued-listing matters for NuCana’s American depositary shares.
NuCana (NASDAQ: NCNA) appointed Ian Webster as Chief Financial Officer effective June 1, 2026. He previously served as Interim CFO since June 2025 and Director of Finance since 2019.
The company highlights his 20+ years of finance experience and notes a cash runway anticipated to extend into 2029 as it advances its oncology pipeline, including the Phase 2 NuTide:701 study of NUC-7738 in combination with Keytruda in PD-1 inhibitor-resistant metastatic melanoma.
NuCana (NASDAQ: NCNA) reported first quarter 2026 results and a clinical update. Cash and equivalents were £21.5 million on March 31, 2026, with a cash runway expected to fund operations into 2029. Net loss was £3.9 million, including £1.9 million of non-cash share-based payments.
The FDA cleared the IND for NUC-7738 in April 2026, enabling US studies initially focused on melanoma. NuCana continues enrollment in the Phase 2 NuTide:701 study of NUC-7738 plus pembrolizumab in PD-1 inhibitor-resistant metastatic melanoma, with final data expected in 2026.
NuCana (NASDAQ: NCNA) reported Q4 and full-year 2025 results and a clinical update on its ProTide pipeline. NUC-7738 showed clinical activity in PD-1 inhibitor-resistant melanoma with partial responses; final Phase 2 expansion data expected in 2026. Cash and equivalents were £24.3M at year‑end, supporting operations into 2029. The company reported a 2025 net loss of £29.4M, reflecting non-cash warrant revaluations and elevated share-based payments.
Key near-term priorities include completing NuTide:701 enrollment, seeking FDA guidance on a registrational path, and advancing NUC-3373 combinations.
NuCana (NASDAQ: NCNA) appointed Theresa Bruce as Chief Operating Officer, effective January 1, 2026. Ms. Bruce brings 25+ years of oncology clinical development experience and previously served as NuCana's Senior Vice President of Clinical Operations and as COO at Nexus Oncology.
Her remit includes advancing the pipeline with planned 2026 data readouts from the Phase 1/2 expansion of NUC-7738 + pembrolizumab (NuTide:701), preparing a registration strategy for NUC-7738, and further characterizing NUC-3373. The company anticipates a cash runway into 2029.
NuCana (NASDAQ: NCNA) presented Phase 2 expansion data for NUC-7738 plus pembrolizumab at ESMO Immuno-Oncology Congress on Dec 10, 2025. The dataset in PD-1 inhibitor‑resistant metastatic melanoma shows clinical activity and a favorable safety profile.
Key results: 2 partial responses (one confirmed), 7 stable disease cases including one ongoing stable disease that converted to a complete metabolic response, and no new safety signals. Nine patients have been treated in the Expansion Cohort; combined with 12 in the Dose Confirmation Cohort the program may include up to 40 patients.
NuCana (NASDAQ: NCNA) reported Q3 2025 results and clinical updates on lead programs NUC-7738 and NUC-3373. The company reported cash and cash equivalents of £25.2m as of Sept 30, 2025 (up from £8.4m at June 30, 2025) after raising £19.0m via an ATM in July 2025 and earlier financing totaling $38.4m in May 2025. NuCana said it is compliant with Nasdaq listing criteria and expects a cash runway into 2029. Clinically, initial expansion data for NUC-7738 are expected in Q4 2025 with final data in 2026; NUC-3373 showed durable responses including an 81% and a 100% reduction in target lesions in individual patients.
NuCana (NASDAQ: NCNA) announced that the China National Intellectual Property Administration granted a composition‑of‑matter patent (ZL 202010794701.2) for NUC‑7738 on Nov 5, 2025.
The patent covers the chemical structure of NUC‑7738 and is expected to be a key element of the program's IP protection, which now includes over 85 issued patents worldwide. NUC‑7738 is a novel anti‑cancer agent in a Phase 1/2 NuTide:701 study combining NUC‑7738 with pembrolizumab for patients with PD‑1 inhibitor refractory or resistant melanoma. The company cited encouraging clinical and translational findings presented at ESMO 2025 and said it aims to expand NuTide:701 to add patients and strengthen the data package.
NuCana (NASDAQ: NCNA) presented preclinical and clinical translational data at ESMO 2025 showing that NUC-7738 synergizes with PD-1 inhibitors in patient-derived organoids from 10 renal cell carcinoma patients, increasing tumor cell killing in co-culture with autologous tumor-infiltrating lymphocytes.
The company said these findings reinforce NUC-7738's mechanism of action and align with results from the ongoing Phase 1/2 NuTide:701 study, which the company reports has shown a favorable safety profile, meaningful tumor volume reduction, and prolonged progression-free survival in PD-1 inhibitor–refractory metastatic melanoma. Regulators approved an expansion to recruit an additional 28 patients, and NuCana plans a meeting with the U.S. FDA to discuss a registration strategy.
NuCana (NASDAQ: NCNA) announced new clinical and preclinical data for NUC-3373 on Oct 14, 2025. Module 1 of the NuTide:303 study treated 12 heavily pre-treated advanced solid-tumor patients with NUC-3373 plus pembrolizumab. Highlights include a 100% reduction in tumor lesion size in a urothelial carcinoma patient who stayed on treatment >15 months, and an 81% reduction in target lesions in a metastatic melanoma patient who remains progression-free at 23 months. Complementary preclinical data (PLOS ONE) show NUC-3373 promotes DAMP release, boosts NK-cell activation, and enhances PD-1 blockade–mediated tumor cell death. The company says it maintains an anticipated cash runway into 2029.
NuCana (NASDAQ:NCNA) has announced its full compliance with all Nasdaq continued listing criteria, including the critical $1.00 minimum bid price requirement. The company has successfully resolved its previously disclosed Nasdaq listing concerns, with formal confirmation received on September 4, 2025.
Executive Chairman Andrew Kay highlighted that the company's current cash position, bolstered by ATM offering proceeds, is expected to fund operations into 2029. This extended runway will support multiple upcoming data readouts and key value-driving milestones in their cancer treatment development programs.